Effect of Oral Semaglutide on Cardiovascular Outcomes in Type 2 Diabetes by Extent of Vascular Disease
Year: 2026
Type: article
Authors: Matthew A. Cavender, Nikolaus Marx, Sharon L. Mulvagh, John E. Deanfield, John B. Buse, Silvio E. Inzucchi, Rodica Pop-Busui, Johannes F.E. Mann, Scott S. Emerson, Neil R. Poulter, Mads D.M. Engelmann, G. Kees Hovingh, Alberto Lorenzatti, Aytekin Oguz, Jose F. Kerr Saraiva, Robinson Sanchez Garcia, Søren Tetens Hoff, Derrick Musinga, Marc P. Bonaca, Ecenur Guder Arslan, Darren K. McGuire
Institutions: University of North Carolina at Chapel Hill, Universitätsklinikum Aachen, RWTH Aachen University, Dalhousie University, University College London, Yale University, Oregon Health & Science University, Friedrich-Alexander-Universität Erlangen-Nürnberg, University of Washington, Imperial College London, Novo Nordisk (Denmark), Instituto Médico DAMIC, Istanbul Medeniyet University, Fundación Cardiovascular de Colombia, University of Colorado Anschutz, University of Colorado Denver, Parkland Health & Hospital System, The University of Texas Southwestern Medical Center
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $7,166
Funder: Novo Nordisk
OpenAlex ID: W7140160672